Introduction
Hypoxia within the ischaemic organ induces maladaptive biochemical responses. Subsequent reperfusion can lead to paradoxical cellular injury, a phenomenon widely known as ischaemia/reperfusion (I/R) injury. 1 Despite the knowledge gathered over the last 30 years no pharmacological strategies have been introduced to rescue the heart muscle in patients with myocardial infarction during reperfusion. 2 A variety of therapeutic attempts, including mechanical conditioning and cyclosporine (an indirect mPTP inhibitor) have all failed so far to enter everyday clinical practice, in spite of positive proof-of-concept studies in experimental animals. 3 Deeper understanding of the molecular events associated with ischaemia and reperfusion may lead to innovative therapeutic strategies for patients with acute myocardial infarction (AMI). Endothelial nitric oxide synthase (eNOS) is constitutively expressed in cardiomyocytes and endothelial cells. 4 Its activity is regulated by several post-translational mechanisms, with phosphorylation being the most extensively studied. 5 eNOS is phosphorylated on serine, threonine and tyrosine residues; this alters the enzyme's ability to produce NO. 5, 6 Phosphorylation of S1177, 7, 8 (S1176 in murine/rat, S1177 in human, and S1179 in bovine eNOS) due to its prominent role in regulating eNOS activity, has attracted most attention, with many studies, too simplistically, equating phosphorylation on this residue with proof of enhanced eNOS activity. Serine 1177 resides in the reductase domain of the enzyme and its phosphorylation makes eNOS sensitive to lower calcium concentrations and increases the flux of electrons through the reductase domain, thus increasing NO production. 6 Another site commonly studied is T495, that is located in the calmodulin (CaM)-binding domain and exerts a negative effect on eNOS activity. 9 Tyrosine phosphorylation of eNOS occurs in endothelial cells treated with tyrosine phosphatase inhibitors or H 2 O 2 and in cells exposed to fluid shear stress. [10] [11] [12] eNOS interacts and is tyrosine phosphorylated by c-Src on Y83. 12 Several agonists like vascular endothelial growth factor, bradykinin, estrogen, and acetylcholine enhance phosphorylation of Y83 and increase eNOS activity. 12, 13 More recently, Y657 was reported to be a critical determinant of its enzymatic activity; phosphorylation of Y657 (Y656 for mouse eNOS) by proline-rich tyrosine kinase 2 (PYK 2) was shown to inhibit eNOS activity.
14 Activation of the phosphoinositide-dependent 3 kinase (PI-3K)/Akt axis leads to S1177 eNOS phosphorylation and enhances NO production; this pathway constitutes a major protective pathway in I/R injury in the heart. 15 The beneficial effects of eNOS-derived NO have been demonstrated both in isolated perfused heart preparations and in vivo by pharmacological, genetic, and gene-therapy approaches. 16, 17 Endogenously generated and exogenously applied NO exerts its beneficial effects either through cGMP/PKG-dependent pathways or by directly targeting the mitochondria. 18, 19 The former pathways have been shown to involve, among others, K ATP channels, the sodium-proton exchanger and PKCe leading to inhibition of mitochondria permeability transition pore opening, 15, 20 while the latter relies on S-nitrosation of complex I to reduce ROS production.
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PYK2 is activated by elevations in calcium and by oxidative stress, both of which are hallmarks of I/R injury. 1 Although PYK2 has been linked to adverse cardiac phenotypic changes, such as hypertrophy 22 and lethal arrhythmias 23 its role in I/R injury remains unexplored. In the present study, we set out to determine whether PYK2 is activated during I/R injury, affecting the ability of eNOS to confer cardioprotection.
Methods

Cell culture
H9c2 cells were cultured in Dulbecco's modified essential medium DMEM. For differentiation, H9c2 were allowed to grow to confluence and were then incubated with DMEM containing 1% FBS containing 10 nM all-trans-retinoic acid. After 7 days cells were elongated, connecting at irregular angles reminiscent of cells with a cardiac phenotype. In addition, differentiation was confirmed by an increase in cardiomyocytespecific markers (troponin and myocyte light chain 2m; see Supplementary material online, Figure S1 ).
In vitro oxidative stress and oxygenglucose deprivation/recovery
To induce oxidative stress injury, H9c2 cells (1.5 x 10 4 per well) were differentiated in 96-well plates. The cells were treated with 500 lM H 2 O 2 in serum-free DMEM for 12 h in a 5% CO 2 incubator at 37 C. In the oxygen glucose deprivation/recovery (OGD/R) assay, differentiated H9c2 cells in 96 well plates were incubated in glucose-free DMEM and subsequently placed in an anaerobic chamber containing a mixture of 95% N 2 and 5% CO 2 at 37 C for 24 h. Following OGD/R, glucose was added to normal levels (final concentration: 4.5 mgÁmL -1
), and cells were incubated under normal growth conditions (95% air and 5% CO 2 ) for an additional 12 h.
MTT and LDH measurements
Following oxidative stress injury or OGD/R; cell survival was assessed in differentiated H9c2 cells by using the conversion of MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to formazan. Cells were incubated with MTT at a final concentration of 0.5 mg/mL, for 2 h at 37 C. The formazan formed was dissolved in solubilization solution (10% Triton-X 100 in acidic 0.1N HCl isopropanol); subsequently, absorbance was measured at 595 nm with a background correction at 750 nm using a microplate reader. Data was normalized as follows. Each OD value was divided by the average value of the respective control group (control in A: no H 2 O 2 , L-NAME or PF-431396; control in B: no H 2 O 2 , L-NAME, scrambled siRNA or PYK2 siRNA; control in C: normoxia without L-NAME or PF-431396; control in D: normoxia without L-NAME, scrambled siRNA or PYK2 siRNA). Lactate dehydrogenase (LDH) release was used to detect cytotoxicity/cell death using a commercially available kit and data normalized as above.
eNOS activity
Enzyme activity was measured using arginine to citrulline conversion by LC-MS, as described in the Supplementary information section.
cGMP enzyme immunoassay
Cyclic nucleotides were extracted by HCl and measured using a commercially available EIA kit (Enzo Life Sciences, P. Zafiropoulos S.A., Greece) following the manufacturer's instructions.
Animals
All animal procedures were in compliance with the European Community guidelines for the use of experimental animals; experimental protocols were approved by the Ethical Committee of the Prefecture of Athens (790/2014). Animals received standard rodent laboratory diet. In the present study, male mice C57BL/6 or male eNOS KO mice were used.
Surgical procedures
The murine in vivo model of ischaemia-reperfusion injury is described in the Supplementary information section.
Experimental protocol
Male mice 10-12 weeks old were anesthetized by intra peritoneal injection with a combination of ketamine, xylazine and atropine (0.01 mL/g, final concentrations of ketamine, xylazine, and atropine 10 mg/mL, 2 mg/ mL, 0,06 mg/kg, respectively). Mice were sham operated or subjected to 30 min LAD occlusion followed by reperfusion for 3, 10, or 30 min. At the end of the experiment, tissue samples from the upper part of the left ventricle (sham or ischaemic part) were excised and snap frozen in liquid nitrogen. In animals treated with the pharmacological inhibitor of PYK2, PF-431396 was administrated at 5 lg/g PF-431396 in 2% DMSO (100 lL) iv 10 min prior to the ischaemic insult. In pilot experiments, using a dose lower than 5 lg/g did not inhibit PYK2 in vivo, while higher doses resulted in transient arrhythmias. In the control group, vehicle (100 lL) containing 2% DMSO in water for injection was administrated iv 10 min prior to the ischaemic insult. In a second series of experiments, mice were subjected to 30 min regional ischaemia of the myocardium, followed by 2 h of reperfusion and were randomized into five groups as follows. (1) control group (n = 8): administration of vehicle (water for injection containing 2% DMSO [100 lL] iv 10 min prior to the ischaemic insult); (2) PF-431396 group A (n = 9): administration of 5 lg/g PF-431396 (dissolved in water for injection containing 2% DMSO; (100lL) iv 10 min prior to the ischaemic insult; (3) PF-431396 group B (n = 7): administration of 5 lg/g PF-431396 (100 lL iv 10 min prior to reperfusion); (4) PF-431396 group C (n = 6): administration of 5 lg/g PF-431396 (100 lL) iv upon reperfusion); (5) eNOS KO group (n = 6): administration of vehicle 10 min prior to the ischaemic insult; (6) eNOS KO þ PF-431396 group (n = 7): administration of 5 lg/g PF-431396 iv 10 min prior to the ischaemic insult.
Statistical analysis
One-way analysis of variance (ANOVA) was used to detect differences between groups or unpaired two-tailed Student's t-test to compare two groups. Post hoc comparisons were made using Tukey's test. A value of P < 0.05 was considered statistically significant. All statistical calculations were performed using Prism 4 analysis software (GraphPad Software, Inc., La Jolla, CA). Data are shown as mean ± SEM values.
Results
3.1 PYK2 increases phosphorylation of eNOS on S1176 and Y656 in cardiomyocytes exposed to H 2 O 2
Exposure of differentiated H9c2 cardiomyocytes to H 2 O 2 for 10 min resulted in increased phosphorylation of PYK2 on the autophosphorylation Y402 activator site ( Figure 1A ; see Supplementary material online, Figure S2A ). In addition, increased phosphorylation of both S1176 and Y656 on eNOS was observed (Figure 1B and C; see Supplementary material online, Figure S2B and C). Pharmacological inhibition of PYK2 by PF-431396 reduced the H 2 O 2 -triggered Y402 phosphorylation of the kinase (see Supplementary material online, Figure S2A ). Moreover, inhibition of the kinase, abolished the phosphorylation induced by H 2 O 2 on both eNOS Y656 (see Supplementary material online, Figure S2B ) and S1176 (see Supplementary material online, Figure S2C ), whilst T495 phosphorylation was unaffected (see Supplementary material online, Figure S2D ). The results obtained with the pharmacological PYK2 inhibitor, were confirmed using a siRNA knockdown approach. Silencing of PYK2 reduced protein levels of PYK2 to 15.3 ± 2.1%, without affecting eNOS levels (eNOS levels after PYK2 siRNA silencing were 106.8 ± 3.3% of control). While PYK2 and eNOS phosphorylation on Y656 and S1176 were induced after exposure to H 2 O 2 in non-transfected or scrambled siRNA-transfected cell, such treatment was ineffective in enhancing eNOS phosphorylation in cells in which PYK2 expression had been silenced ( Figure 1A -C).
Increased S1176 phosphorylation of eNOS is PYK2-PI3K-Akt mediated
As PYK2 is a tyrosine kinase, the observation that PYK2 enhanced S1176 eNOS phosphorylation suggested the existence of an intermediate kinase that would lie downstream of PYK2 and could phosphorylate S1176. H 2 O 2 treatment increased Akt phosphorylation in H9c2 cells ( Figure 2A ). This effect was inhibited both by pharmacological inhibition of PYK2 (Figure 2A ), as well as by PYK2 silencing ( Figure 2B) . Moreover, immunoprecipitation experiments demonstrated that the PI-3K subunit p85 was phosphorylated on Y458 and associated with PYK2 in H 2 O 2 -treated cells (see Supplementary material online, Figure S3A ). Activation of PI-3K, as assessed by p-p85, was abolished both by inhibiting the activity of PYK2 (see Supplementary material online, Figure S3B ), as well as by silencing of PYK2 (see Supplementary material online, Figure S3C ).
The dominant phosphorylation site determining eNOS activity is Y657
Although Y657 (Y656 for the mouse) phosphorylation is known to inhibit eNOS activity, 24 it is unknown whether the negative impact of Y657 phosphorylation on eNOS activity prevails over the positive effect of S1177 when both residues are phosphorylated. We generated human eNOS mutants for Y657 and S1177 by converting the residues to the phosphomimetic aspartic acid (D). HEK293 cells were transfected with empty vector, wild-type eNOS, eNOS Y657D, and the Y567D/S1177D double mutant; all mutants exhibited equal eNOS expression ( Figure 3A ). Cells transfected with wild-type eNOS showed an increased ability to convert arginine to citrulline. Y657D eNOS was completely inactive ( Figure 3B ), in line with our previous observations 24 ). The double phosphomimetic Y657D/S1177D mutant-unlike what has been shown for the S1177D that expresses higher activity than wild-type eNOS 7, 8, 25 exhibited no basal or stimulated eNOS activity.
PYK2 inhibition or knockdown rescues cardiomyocytes from oxidative stress injury or OGD/R by alleviating eNOS inhibition
Oxidative stress injury of H9c2 cells following exposure to H 2 O 2 resulted in reduced formation of formazan after incubation with MTT ( Figure 4A and B) . In addition, cells exposed to H 2 O 2 exhibited increased LDH release (see Supplementary material online, Figure S5 ). Treatment with L-NAME or PF-431396 under basal conditions did not alter LDH release or only minimally affected their ability to convert MTT. However, pharmacological inhibition of PYK2 in the context of oxidative stress injury significantly reduced cell toxicity ( Figure 4A , see Supplementary material online, Figure S4A ). The beneficial effect of PF-431396 was reversed upon inhibition of eNOS by L-NAME ( Figure 4A ; see Supplementary material online, Figure S4A ). The results were replicated by silencing PYK2; reducing expression of the kinase rendered the cells less susceptible to injury. The cytoprotective effect of PYK2 silencing was reversed by eNOS inhibition ( Figure 4B ; see Supplementary material online, Figure S4B ).
Additional evidence for the protective effects of PYK2 inhibition in H9c2 was provided in experiments in which H9c2 were subjected to oxygen/glucose deprivation (OGD) injury. Pharmacological inhibition of PYK2 ( Figure 4C ; see Supplementary material online, Figure S4C ) or PYK2 knockdown ( Figure 4D ; see Supplementary material online, Figure S4D ) increased cell survival, as assessed by MTT conversion and LDH release. Similarly to what was seen with H 2 O 2 , the beneficial effects of PYK2 inhibition in cells exposed to OGD were prevented by L-NAME ( 
Time-dependent phosphorylation of PYK2 and eNOS in I/R
To test the validity of our cell-based findings in vivo, changes in PYK2 and eNOS phosphorylation were monitored at different time points of I/R following LAD ligation in mice. In these experiments, we observed increased phosphorylation of PYK2, within minutes of reperfusion ( Figure 5A Figure 5A ). Akt and S1176 eNOS phosphorylation were reduced at the end of ischaemia; phosphorylation started to increase during early reperfusion ( Figure 5B ). In contrast, Thr495 phosphorylation remained unchanged throughout the time course studied ( Figure 6A) . To evaluate the amount of NO produced at the end of ischaemia and during reperfusion, cGMP was measured as a surrogate marker of biologically active NO. cGMP levels were reduced at the end of the ischaemic insult. cGMP levels reached a trough at the 3rd minute of reperfusion, when the highest levels of eNOS Y656 phosphorylation were observed ( Figure 6B) , increasing thereafter paralleling Y656 de-phosphorylation.
Inhibition of PYK2 enhances eNOS signaling and reduces infarct size following ischaemia/reperfusion
Administration of the PYK2 inhibitor in mice subjected to myocardial infarction, resulted in reduced PYK2 autophosphorylation ( Figure 7A ), which in turn lead to attenuated phosphorylation of eNOS on Y656 ( Figure 7B ) in the early phase of reperfusion. Similarly, eNOS S1176 phosphorylation was reduced in the presence of PF-431396 ( Figure 7C ). In line with the observation that Y656 is the dominant phosphorylation event, cGMP levels increased at the 3rd minute of reperfusion in the presence of a PYK2 inhibitor ( Figure 7D ), in spite of the lower S1176 phosphorylation.
To test whether PYK2 inhibition affects infarct size, mice were treated with PF-431396 prior to the onset of ischaemia (group A), at the end of ischaemia (group B) or upon reperfusion (group C). PF-431396 did not alter heart rate or mean arterial blood pressure (data not shown). The animals treated with PF-431396 in cohorts A and B exhibited a significant reduction of the myocardial infarct size vs. the control group (17.9% ± 1.8%, 17.0% ± 2.7% respectively vs. the infarct size in the control group: 45.4% ± 3.9%) ( Figure 8A and C) . However, pharmacological inhibition of PYK2 upon reperfusion did not reduce myocardial infarct size (39.3% ± 1.9% vs. the infarct size in the control group: 45.4% ± 3.9%) ( Figure 8A and C). The area at risk was similar among groups ( Figure 8B ). The beneficial effect of the PYK2 inhibitor was absent in eNOS KO mice, suggesting that PF-431396-induced protection is eNOS-dependent ( Figure 8B ). Areas at risk were not different among the treatments in eNOS KO mice ( Figure 8B) 
Discussion
The main findings of the present study are: (1) PYK2 is activated in response to oxidative stress in cardiomyocytes in vitro and during ischaemia/reperfusion in vivo, (2) once activated, PYK2 promotes dual phosphorylation of eNOS on S1177 and Y656, (3) Y656 phosphorylation has a marked inhibitory effect on eNOS activity, (4) activation of PYK2 results in decreased cardiomyocyte viability in vitro and in vivo, (5) PYK2 inhibition alleviates the inhibitory effect of Y656 phosphorylation on eNOS, thereby removing the blockade of NO production, which, in turn, results in a reduction of infarct size.
PYK2 is a non-receptor tyrosine kinase that can be activated by calcium 26 and stress signals. 27 PYK2 is a redox-sensitive kinase, since its activation occurs following exposure to oxidative stress or in response to agents that promote ROS production, like angiotensin II and endothelin-1. 14,28,29 PYK2 activation in the heart has been previously linked to cardiac remodeling, 30 hypertrophic responses 22, 31 and 33 Since PYK2 has been shown to promote eNOS phosphorylation both directly on Y656 24 and indirectly on S1176 through PI-3K/Akt, 34 we examined the ability of H 2 O 2 to trigger PYK2-mediated eNOS phosphorylation on these residues in cultured cardiomyocytes. Indeed, we found that exposure to H 2 O 2 increased phosphorylation of eNOS on both S1176 and Y656. In line with our observations, Sartoretto et al.
reported that H 2 O 2 increases phosphorylation on S1176 of eNOS in H9c2 in a Ca 2þ -dependent manner. 35 In subsequent experiments, we found that PYK2 inhibition reduced phosphorylation on both sites, We recently reported that the phosphorylation of human eNOS on Y657 by PYK2 abolishes eNOS activity; mutation of Y657 to glutamate or aspartate eliminated NO generation. 24 However, the effect of Y657 phosphorylation on eNOS activity when S1177 is also phosphorylated has not been examined. We, thus, transfected HEK293 cells with the Y657D/S1177D phosphomimetic mutant and compared its activity with that of wild-type and Y657D eNOS. We observed that eNOS activity of the Y657D/S1177D eNOS wase severely impaired, similar to that of Y657 eNOS. Thus, phosphorylation of Y657 exhibits a dominant effect over S1177, blocking eNOS activity irrespectively of the phosphorylation status of the serine residue. Y656 lies in the FMN-binding domain and phosphorylation of this residue likely interferes with electron flow by locking the FMN domain in its electron acceptor position and greatly suppressing eNOS activity. 24 Our findings may also explain why some agents that increase S1177 phosphorylation, such as insulin, fail to increase NO production. 24 To correlate the biochemical observations to functional responses, we performed cell viability assays in cells exposed to H 2 O 2 , assessing either MTT conversion, or cell membrane integrity by measuring LDH release. We observed that inhibition of PYK2 kinase rendered the cardiomyocytes less susceptible to injury in response to H 2 O 2 and oxygen/ glucose deprivation. In line with our findings, chronic PYK2 activation was correlated to increased cardiomyocyte death in heart failure. 37 Interestingly, the beneficial effect of PYK2 blockade was prevented by eNOS inhibition. Published reports have so far studied PYK2 and NO as independent variables in cardiomyocyte survival. The present series of experiments connects the two pathways and supports the hypothesis that PYK2 activation during oxidative stress injury inactivates eNOS, minimizing NO bioavailability, thus, leading to increased cell death. Inhibition of PYK2 restores eNOS functionality, exerting a protective effect in response to noxious stimuli. It should be noted that PF-431396 is a more potent inhibitor of FAK (IC 50 = 2 nM) than PYK 2 (IC 50 = 11 nM) and protective roles for FAK have been previously reported in myocytes. 38 Use of any pharmacological inhibitor raises questions regarding possible off-target effects. However, the fact that we have obtained similar results after siRNA knockdown of PYK2 argues in favor of a role for PYK2 in the cardioprotective responses.
To test the relevance of our in vitro findings, we used a mouse model of LAD ligation. In these experiments, we observed that PYK2 phosphorylation (and presumably activity) is low at the end of ischaemia; early during reperfusion PYK2 activity shows a peak and phospho-PYK2 levels return to baseline levels soon after that. The kinetics of PYK2 activation are reminiscent of the kinetics of ROS generation that are formed in high amounts early in reperfusion, 39, 40 leading us to speculate that ROS are, indeed, an endogenous trigger for enhanced PYK2 activity. In line with the fact that eNOS is a substrate for PYK2, Y656 showed an identical time course of phosphorylation demonstrating higher levels 3 min after the onset of reperfusion. In contrast, Akt and S1176 phosphorylation are lowest at the end of the ischaemic period and increase after reestablishing blood flow. A similar time course of Akt and eNOS S1176 phosphorylation has been reported by Inserte et al. who observed low eNOS S1176 phosphorylation at the end of ischaemia that gradually increased towards normoxic levels in isolated perfused hearts. 41 Other investigators have also reported low Akt phosphorylation at the end of ischaemia. 42 The low level of S1176 phosphorylation we observed at the onset of reperfusion correlates well with the finding that eNOS activity declines throughout ischaemia 43 and is further supported by finding by Cai et al. 44 who showed a time-dependent decrease on S1176 phosphorylation with ischaemia. On the other hand, T495 phosphorylation similarly to what was observed in vitro remains unaltered, suggesting that this residue does not contribute to changes in eNOS activity during I/R. No changes on T495 during I/R were also reported by other investigators. 45 To determine the effect of altered eNOS phosphorylation status on eNOS activity, we measured cGMP, as a surrogate marker of biologically active NO. Previous studies have found cGMP levels to be reduced after I/R. 46, 47 In our experiments, cGMP levels were low at the end of ischaemia and dropped even further at the 3rd minute of reperfusion, paralleling the increase in phosphorylation in the dominant eNOS Y656 site. Thereafter, cGMP levels began to rise reflecting the drop in Y656 and the increase in S1176 phosphorylation. NO production from eNOS during I/R is known to be limited by BH 4 availability, eNOS coupling and dimerization 41, 43 and intracellular acidification 48 ; NO during I/R injury is also quenched by superoxide anions. 49 All of these factors in addition to changes in phosphorylation, could contribute to lower levels of biologically active NO. To test for causality between enhanced Y656 phosphorylation and low NO output in vivo, we determined cGMP levels at the 3rd minute of reperfusion in the presence and absence of a PYK2 inhibitor PF-431396. Pharmacological inhibition of PYK2 reduced eNOS Y656 phosphorylation and enhanced cGMP accumulation, providing evidence that NO output is augmented. Treatment with the PYK2 inhibitor, similarly to what was observed in our in vitro experiments, also reduced S1176 phosphorylation. The increase in NO production by eNOS when S1176 is hypo-phosphorylated can be explained as follows. S1176 phosphorylation serves to sensitize eNOS to lower calcium concentrations; however, the sustained increase in intracellular calcium known to occur during early reperfusion 1 likely suffices to drive eNOS activity without the need for enhanced S1176 phosphorylation. Thus, reducing Y656 phosphorylation by inhibiting PYK2 during reperfusion, derepresses eNOS activity, and is the key event in enhancing NO output.
To assess the functional implications of alterations in the pattern of eNOS phosphorylation, we measured myocardial infarct size in vivo. In agreement to our biochemical and in vitro observations, we found that pharmacological inhibition of PYK2 kinase throughout ischaemia or immediately prior to reperfusion prevents the decline in eNOS activity in the critical initial minutes of reperfusion, reducing myocardial infarct size. The lack of effectiveness of PF-431396 when administered upon reperfusion is likely attributed to pharmacokinetics; ROS generated intracellularly once blood flow is re-established can activate RYK2 faster than the inhibitor can cross the plasma membrane and reach its target. To test whether the action of the PYK2 inhibitor PF-431396 is eNOSdependent, we repeated the experiments in eNOS KO mice. Interestingly, in spite of the importance of eNOS in cardioprotectionand in line with what has been shown by other investigators 42, 50 -we observed that infarct size in eNOS KO mice was comparable to that of wild-type controls. Importantly, the cardioprotective effect of PYK2 inhibition was abolished mice lacking eNOS, further supporting our conclusion that tyrosine phosphorylation of eNOS in Y656 is a major determinant of infarct size. The finding that S1176D eNOS knocking mice are protected from I/R injury 42 is not in conflict with our hypothesis for a dominant role of Y656 on eNOS activity. Mice expressing a constitutively overactive eNOS would be conditioned by the higher NO amounts present before and during ischaemia. Moreover, since not all of the cellular eNOS is expected to be phosphorylated on Y656 at the 3rd minute of reperfusion, S1176D eNOS mice would be expected to have higher levels of NO than wild-type mice. Our experimental design did not allow us to conclude whether endothelial or cardiomyocyte PYK2 is targeted. However, it has been reported that endothelial derived NO during I/R injury plays a relatively minor role compared to cardiomyocyte-derived NO, 51 suggesting that the cellular target for PF-431396 lies within the cardiomyocytes. Study limitations. Our initial experiments with cultured cells utilized a myoblast cell line that was differentiated into myocytes; while working out in vitro the signaling events leading to eNOS Y656 phosphorylation it would have been better if native, freshly isolated cardiomyocytes had been used. In the animal experiments, measuring eNOS activity and/or Figure 8 Inhibition of PYK2 is cardioprotective in wild-type, but not eNOS KO mice. Mice were subjected to LAD ligation and infracted area, area at risk and total area were determined. (A) Infarcted to area at risk ratio as % (% i/r). n = 8 for control group, n = 9 for PF-431396 group A, n = 7 for PF-431396 group B; n = 6 for PF-431396 group C, n = 6 for eNOS KO group, and n = 7 for PF-431396 (group A) in eNOS KO group; *P < 0.05 vs. wt control. (B) Ratio of area at risk to whole myocardial area. P = NS among groups. (C) photomicrographs of representative pictures from different treatment groups.
PYK2, eNOS and cardioprotection NO levels is not trivial. Although cGMP levels are a good measure of biologically active NO, they are not synonymous to eNOS activity. cGMP is produced both by soluble guanylate cyclase and by the NO-independent particulate guanylate cyclase pathway; its levels are not determined only by the cyclase synthetic activity, but also by the phosphodiesterasemediated degradation. Moreover, different sub-cellular pools of cGMP exist in cardiomyocytes, adding another level of complexity.
Targeting NOx to limit the injurious effect of acute myocardial infarction has inherent limitations. 52, 53 For example, patients with cardiovascular disease are often already on medications that act to increase NO action or bioavailability; administering an agent that increases NO levels would exert limited, if any, protection. Moreover, given the bell-shaped effects of NO, the dose of any agent increasing NO should be titrated carefully, so as not to expose the myocardium to toxic NO amounts. An additional, significant limitation of our study is the lack of ROS measurements in vitro and in vivo that could provide mechanistic insights into PYK2 activation and link activation of this kinase to cardiomyocyte injury. Finally-as with the many other experimental treatments that have failed during translation-the current observations were made in otherwise healthy animals. The effectiveness of PYK2 inhibition in I/R injury would have to be also tested in animal models with co-morbidities and/or after co-administration of other commonly prescribed medications. In summary, the current report unveils a novel, negative regulatory role for PYK2 in myocardial I/R injury and links the PYK2 pathway to eNOS. PYK2 activation results in dual eNOS phosphorylation: a direct phosphorylation on eNOS Y656 and an indirect, Akt-mediated phosphorylation on Ser1176. The functional consequence of these post-translational modifications is a marked reduction of NO output in the early minutes of reperfusion, which allows myocardial cell death. Thus, pharmacological inhibition of PYK2, and, consequently, de-repression of eNOS activity emerges as a novel potential therapeutic approach to limit myocardial I/R injury.
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